Avadel Pharmaceu Stock Price, News & Analysis

Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced that its management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:00 p.m. ET. A live webcast and archived recording of the chat will be accessible on Avadel’s Investor Relations website for 90 days post-conference. Avadel is focused on innovative biopharmaceutical solutions, particularly an investigational sodium oxybate formulation aimed at treating cataplexy and excessive daytime sleepiness in adults with narcolepsy. For further details, visit www.avadel.com.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced on February 3, 2023, the approval from its Compensation Committee to grant non-statutory options for 38,000 ordinary shares to two new employees. This move is in line with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new hires as part of the 2021 Inducement Plan. The options will have a ten-year term and vest gradually over four years, starting with 25% vesting on the first anniversary. Avadel focuses on innovative solutions for medicine and is known for its investigational drug, LUMRYZ™, aimed at treating narcolepsy.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) has published significant real-world data on the adverse events linked to dosing errors of immediate-release oxybate. The study reveals that of 541 reports analyzed, 177 were serious, with 41 cases resulting in adverse events due to early second dose intake. Notably, 22% required emergency services and 27% led to hospitalizations, highlighting the risks of the current dosing schedule. The analysis calls for greater awareness among medical professionals and patients, as current labeling lacks information on these risks. The company suggests that an upcoming once-nightly formulation could potentially mitigate these dosing errors.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced the approval of non-statutory options by its Compensation Committee to three new employees. The aggregate of 40,500 ordinary shares will be granted under Avadel's 2021 Inducement Plan. These options come with a ten-year term and will vest over four years, with the first 25% vesting on the one-year anniversary. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent joining the biopharmaceutical company focused on innovative medication solutions, including its lead drug candidate, LUMRYZ™.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced the grant of non-statutory options to six new employees, allowing them to purchase 105,000 ordinary shares under the 2021 Inducement Plan. This decision was made by the Compensation Committee and is in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of employment. This initiative is aimed at attracting talent while adhering to regulatory requirements.

Acadia Pharmaceuticals has appointed Dr. Doug Williamson as Executive Vice President, Head of Research and Development. Dr. Williamson, succeeding Dr. Srdjan Stankovic, brings over 20 years of neuroscience R&D experience, most recently serving as Chief Medical Officer at Avadel Pharmaceuticals. His leadership is expected to play a crucial role as Acadia prepares for the potential approval of trofinetide for Rett syndrome and advances its clinical programs. This strategic move aims to strengthen Acadia's position in the neuroscience market during a pivotal time.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced the grant of non-statutory options for 30,000 shares to a new employee as part of its 2021 Inducement Plan. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on the employee's continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4). Avadel is focused on innovative medication development, including its lead candidate LUMRYZ™, an investigational treatment for narcolepsy. For further information, visit www.avadel.com.

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its participation in two upcoming investor conferences. Management will engage in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:30 p.m. ET, and at the Evercore ISI HealthCONx Conference on December 1 at 2:40 PM ET. Live webcasts and archived recordings will be accessible on Avadel’s Investor Relations website for 90 days post-conference. Avadel focuses on innovative treatments like LUMRYZ™, aimed at addressing narcolepsy symptoms.

Avadel Pharmaceuticals (Nasdaq: AVDL) announced that the U.S. District Court for Delaware has ordered Jazz Pharmaceuticals to delist U.S. Patent No. 8731963, known as the REMS Patent, from the FDA's Orange Book. This ruling may accelerate FDA approval for LUMRYZ™, an investigational sodium oxybate formulation for treating narcolepsy symptoms. LUMRYZ already received tentative FDA approval in July 2022, pending the REMS Patent's status. Avadel aims to collaborate with the FDA to finalize approval and make LUMRYZ available to patients with narcolepsy.